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Abstract
Background: The implementation of a protocol has been associated with improvements in the processes of care
in clinical settings. Although stress ulcer prophylaxis is recommended for critically ill patients at high risk, there is
currently no consensus on its use. Therefore, we herein developed a protocol for stress ulcer prophylaxis, and
evaluated therapeutic outcomes in a before-after study.
Methods: The protocol was developed by considering the effectiveness, disadvantages (including adverse events)
and cost of each agent based on previous findings. Patients who were admitted to the 8-bed emergency intensive
care unit (ICU) of our hospital for more than 24 h during the year before and after implementation of the study
were eligible. Each investigation item was evaluated retrospectively.
Results: There were 211 and 238 study patients before and after implementation of the protocol, respectively. The
baseline characteristics of patients on/during ICU admission were similar in the two groups. The proportion of
medicated patients was 79.6 % before and 84.5 % after protocol implementation. Before implementation of the
protocol, 4.3 % of patients developed clinically important gastrointestinal bleeding, and this incidence decreased
significantly to 0.8 % after its implementation (P = 0.019). The frequency at which medication was discontinued due
to adverse events was slightly lower after implementation of the protocol. No significant differences were observed
in the costs of stress ulcer prophylactic agents or mortality in the ICU.
Conclusions: The results of the present study indicated that the development and implementation of a protocol
for stress ulcer prophylaxis, for which there are currently no criteria, improved a main outcome, clinically important
gastrointestinal bleeding.
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Background
Stress ulcers are superficial lesions generally, but not ex-
clusively involving the mucosal layer of the stomach, and
commonly occur in critically ill patients [1]. Most critic-
ally ill patients have endoscopically detectable mucosal
erosion and subepithelial hemorrhage within 24 h of
admission to an intensive care unit (ICU) [2]. The
frequency of clinically important gastrointestinal (GI)
bleeding in patients not receiving prophylaxis reportedly
ranges from 0.1 to 39 % [1]. The mortality rate is 48.5 %
in ICU patients with clinically important bleeding, in
contrast to 9.1 % in those without bleeding [3]. There-
fore, it has been recommended that stress ulcer prophy-
laxis should be implemented in patients at high risk.
Approaches to stress ulcer prophylaxis include medi-
cation with pharmacological agents and enteral nutrition
[1, 2, 4–11]. Agents known to provide stress ulcer
prophylaxis include antacids, prostanoids, sucralfate,
histamine-2 receptor antagonists (H2RAs) and proton
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pump inhibitors (PPIs). The efficacy and safety of H2RAs
and PPIs in particular have been investigated in recent
studies [5–9]. In some studies, the effects of PPIs and
H2RAs were found to be similar, whereas others indicated
that PPIs decreased the risk of GI bleeding more than
H2RAs [6–8]. A recent study suggested that PPIs were as-
sociated with a greater risk of GI hemorrhage, pneumonia
and Clostridium difficile infection than H2RAs in mechan-
ically ventilated patients [12]. Therefore, both agents have
advantages and disadvantages in clinical settings [5, 6].
Although various approaches to stress ulcer prophy-
laxis have been reported, there is limited evidence for
and no consensus on their efficacy and safety. Few stud-
ies have proposed and examined criteria for selecting
stress ulcer prophylactic agents. Since critically ill
patients characteristically require various therapies, the
absence of a therapeutic strategy potentially leads to in-
appropriate medication, which may have a negative im-
pact on the process of care. An appropriate approach to
stress ulcer prophylaxis based on the clinical characteris-
tics of the patient, which are diverse and may vary from
hour to hour, is considered necessary. The implementa-
tion of protocols has been associated with improvements
in the processes of care in clinical settings [13]. There-
fore, the development of a protocol for stress ulcer
prophylaxis may improve the process of care in critic-
ally ill patients. In the present study, we devised a
protocol for stress ulcer prophylaxis, and evaluated
therapeutic outcomes in the ICU before and after its
implementation.
Fig. 1 Protocol for stress ulcer prophylaxis in ICU patients. The upper panel shows the recommended procedure according to risk factors for
stress ulcer prophylaxis. In patients with one or more of the listed factors, medication was considered according to the flowchart. A patient with
risk factors 1 or 2 almost always received medication. When it was not possible to administer a particular agent or a patient’s condition had
changed, including the possibility of oral administration, another agent was administered according to the flowchart. Recommended adjustments to
the dosage of famotidine according to renal function are shown in the lower panel. Ccr, creatinine clearance; HD, hemodialysis; INR, international
normalized ratio; PTT, partial thromboplastin time
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Methods
Development and implementation of a protocol for stress
ulcer prophylaxis
A protocol was developed by intensive care specialists
and clinical pharmacists, who considered the effective-
ness of stress ulcer prophylaxis, adverse effects and in-
teractions and cost of each agent, with data being drawn
from published studies and Japanese drug package in-
serts (Fig. 1). Risk factors were determined as reported
previously [1–4, 6]. Medical care was mainly based on
the resultant protocol. However, where necessary, physi-
cians were allowed the flexibility to individualize medica-
tion according to a particular patient’s characteristics,
including the generation of GI bleeding and continu-
ation of antiulcerogenic agents that were being taken
prior to ICU admission.
The protocol was implemented from January 2013 for
patients who fit the eligibility criteria. Intensive care
physicians generally prescribed the agents specified by
the protocol. In addition, pharmacists checked the pa-
tients’ conditions and medications nearly every day, and
proposed changes to the physicians when the medica-
tions were not in accordance with the protocol.
Design, setting and participants
This was a retrospective observational before-after study.
Patients who were admitted to the 8-bed emergency
ICU in Kobe City Medical Center General Hospital, a
700-bed general hospital, between January and December
2012 (before implementation of the protocol) or between
January and December 2013 (after its implementation),
were enrolled. Patients were excluded if they were younger
than 20 years, had GI bleeding on ICU admission, or were
discharged within 24 h of admission. Although study pa-
tients admitted to the ICU for less than 24 h were ineli-
gible for this study, the protocol was also used to select
their treatment.
Outcome measures
Baseline characteristics, including sex, age, the presence
or absence of intubation, coagulopathy, trauma and burns
on/during ICU admission, medication status and out-
comes were evaluated. The medication status included
medication or not, the types and number of agents used
for stress ulcer prophylaxis, dosages, duration of adminis-
tration, adverse events and costs during the ICU stay.
Medicated patients were defined as those who received
one or more of the following stress ulcer prophylactic
agents: intravenous lansoprazole, omeprazole, cimetidine,
famotidine and ranitidine; and oral esomeprazole, lanso-
prazole, omeprazole, rabeprazole, famotidine, ranitidine
and sucralfate. Costs included those of the agents them-
selves, but not of the devices used to administer the medi-
cation, nutrition or treatment of adverse effects caused by
the agents. Prices were calculated in Japanese yen. Adverse
events caused by stress ulcer prophylactic agents were
evaluated from the medical records. The studied out-
comes of application of the protocol included the number
of patients with GI bleeding and their baseline characteris-
tics, duration of stay and mortality in the ICU. Clinically
important bleeding was defined as reported by Krag et al.
[5]. Each investigation item was evaluated retrospectively
using the electronic health record system.
Statistical analysis
Differences before and after implementation of the proto-
col were evaluated statistically by the two-sample χ2 test
of proportions (baseline characteristics including sex,
number of intubated patients, patients with coagulopathy,
trauma and burns, number of patients who received stress
ulcer prophylactic agents, clinically important GI bleeding
and mortality in the ICU), or the Mann-Whitney U test
(age, medicated days, total cost of stress ulcer prophylactic
agents, and duration of the ICU stay). Significance was set
at P < 0.05.
Ethics
This study was approved by the Institutional Review
Board of Kobe City Medical Center General Hospital
and the Board waived the need for patients’ consent
(No. 1303-jn4).
Results
In this study, 211 and 238 patients were eligible before
and after introduction of the protocol for stress ulcer
prophylaxis, respectively. Their baseline characteristics
on/during ICU admission are shown in Table 1. Distri-
bution of sex and of diagnosis and treatment depart-
ment, and age were similar in the two groups. No
significant differences were observed in the number of










Sex Male 132 (62.6 %) 157 (66.0 %) 0.452
Female 79 (37.4 %) 81 (34.0 %)




Medical 110 (52.1 %) 122 (51.3 %) 0.974
Surgery 40 (19.0 %) 47 (19.7 %)
Others 61 (28.9 %) 69 (29.0 %)
Intubation 96 (45.5 %) 101 (42.4 %) 0.514
Coagulopathy 91 (43.1 %) 106 (44.5 %) 0.764
Trauma 44 (20.9 %) 38 (16.0 %) 0.181
Burns 8 (3.8 %) 5 (2.1 %) 0.286
aValues are presented as the median (range)
Ikemura et al. Journal of Pharmaceutical Health Care and Sciences  (2015) 1:33 Page 3 of 6
intubated patients or patients with coagulopathy, trauma
or burns. The distribution of diagnoses and treatments
was also similar.
The only pharmacological agents administered for
stress ulcer prophylaxis were PPIs and famotidine; raniti-
dine, sucralfate; the other types of stress ulcer prophylac-
tic agents were not chosen. The proportion of medicated
patients after introduction of the protocol was slightly
higher than that of before the introduction, 84.5 and
79.6 %, respectively (Table 2). The frequency of choice of
particular stress ulcer prophylactic agents was similar;
however, oral lansoprazole was used more frequently
and oral famotidine less frequently after implementation
of the protocol. Furthermore, the dosages differed. For
example, the proportion of patients who received 15 mg
of lansoprazole increased (from 31.5 to 52.7 %), whereas
the proportion who received 30 mg decreased (from
14.9 to 7.5 %). Before introduction of the protocol,
20 mg famotidine was administered to most patients,
both orally and intravenously and the dosage was not al-
ways adjusted for renal function. Consequently, the pro-
portion of patients receiving 40 mg was higher after
introduction of the protocol. Discontinuation of the medi-
cation because of definite or suspected adverse events oc-
curred less frequently after introduction of the protocol,
decreasing from 6.6 to 3.8 %. The duration of administra-
tion and costs of stress ulcer prophylactic agents were
similar in the two groups of patients (Table 2).
Table 3 summarized the outcomes of implementation
of the protocol for stress ulcer prophylaxis. Mortality
and stay in the ICU were similar in the two groups. The
number of patients with clinically important GI bleeding
significantly decreased after introduction of the protocol
(from 4.3 to 0.8 %; P < 0.05). Before its introduction, 5
out of 9 patients with GI bleeding had not received
stress ulcer prophylactic agents even though they were
at high risk. PPIs and H2RAs were both contraindicated
in 3 of these patients because of their adverse events.
Furthermore, 3 patients received omeprazole or rabepra-
zole via a gastric tube before introduction of the proto-
col. However, this did not occur after introduction of the
protocol, when most patients received the medication
specified by the protocol. Exceptions included continu-
ation of an antiulcerogenic agent that a patient had been
taking prior to ICU admission, and the administration of
no medication to patients receiving enteral nutrition.
Among the patients with clinically important GI bleed-
ing, 2 and 0 patients died in the ICU before and after
the implementation of the protocol, respectively. Their
direct cause of death was not GI bleeding.
Discussion
Previous studies demonstrated that protocols improved
the processes of care [13]. Although recent studies pro-
vided recommendations, few protocols for stress ulcer
prophylaxis that detail agents and dosages have been
published [9, 14]. Therefore, we developed the protocol
presented herein to provide criteria for stress ulcer
prophylaxis, including risk factors, agents, dosages and
routes, based on previous findings (Fig. 1). Confirmation
by clinicians and pharmacists prevented the use of un-
necessary medication and omission of medication. As a
result, more patients were medicated after implementa-
tion of the protocol despite similar baseline characteristics
on/during ICU admission before and after implementa-
tion (Tables 1 and 2). This is because some patients did
not receive necessary medication for stress ulcer prophy-
laxis because of the absence of a protocol. Therefore, im-
plementation of the protocol was expected to augment
the processes of care in critically ill patients.
The duration and cost of medications for stress ulcer
prophylaxis were similar before and after introduction of
the protocol (Table 2). In some circumstances the dur-
ation and cost decreased; for example, fewer patients re-
ceived the agents as therapy for GI bleeding, not as
prophylaxis, after implementation of the protocol. Other
situations increased the duration and cost, such as when
fewer patients at high risk of stress ulcers did not receive
medication after implementation. Furthermore, the cost
was decreased by earlier switching to oral administra-
tion. Conversely, standardization of the dosage of H2RAs
based on renal function increased the average dosage.
Before introduction of the protocol, 4.3 % of patients
had clinically important GI bleeding (Table 3), which
was consistent with previously reported rates [8]. This











Medicated patients 168 (79.6 %) 201 (84.5 %) 0.182
Duration of
administration (days)a
3.0 (0–36) 2.5 (0–46) 0.586
Cost (yen)a 538 (0–10,198) 536 (0–8,404) 0.573
aValues are presented as the median (range)













9 (4.3 %) 2 (0.8 %) 0.019
Mortality in ICU 19 (9.0 %) 22 (9.2 %) 0.930
ICU stay (days)a 5.0 (2–59) 4.0 (2–49) 0.195
aValues are presented as the median (range)
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finding indicated that the medical care provided prior to
protocol implementation was not substandard. After
introduction of the protocol, significantly fewer patients
had clinically important GI bleeding (0.8 %) (Table 3), an
improvement we attributed to the implementation of the
protocol. Before introduction of the protocol, some pa-
tients with GI bleeding had not received stress ulcer
prophylaxis even though they were at high risk, partly
because of adverse events and also because there were
no clear criteria for selecting appropriate prophylactic
agents. The protocol presented here includes multiple
strategies to cover situations in which it is not possible
to continue the administration of a particular agent. Fur-
thermore, the protocol recommends minimum effective
dosages, which may decrease the frequency of adverse
events. Since adverse events occurred less frequently,
medication was discontinued less often, a possible reason
for the lower incidence of GI bleeding. Prior to introduc-
tion of the protocol, some patients with GI bleeding re-
ceived agents that cannot be administered via a gastric
tube, including omeprazole and rabeprazole. These medi-
cations may have been ineffective for stress ulcer prophy-
laxis. The protocol did not include these agents owing to
risk management considerations; therefore, they were
rarely selected after its introduction.
While the number of patients with clinically important
GI bleeding was decreased after the implementation of
the protocol, mortality in ICU was similar in two groups
(Table 3). The mortality rate is known to be dramatically
increased in patients with clinically important GI bleeding
[3]. Generally, a number of fatalities might be decreased,
as a number of patients with clinically important GI bleed-
ing are decreased. In this study, few patients with clinically
important GI bleeding died in ICU. Therefore, mortality
in ICU was not affected by the frequency of clinically im-
portant GI bleeding.
There were some limitations in our evaluation of the
protocol. Although pneumonia is known to be one of the
major adverse events associated with stress ulcer prophy-
lactic agents, we did not evaluate its frequency because
many patients had pulmonary disease on ICU admission.
Previous studies suggested that acid-suppressive agents in-
creased the risk of pneumonia [15, 16], and that this may
be mediated by the growth of gastric flora with increasing
pH [17]. In the present study, mortality and the ICU stay
were similar before and after introduction of the protocol,
suggesting that there was no increase in the frequency of
pneumonia.
Conclusions
The use of our protocol for stress ulcer prophylaxis,
which was designed based on previous findings, resulted
in a decrease in the frequency of clinically important GI
bleeding in critically ill patients. These results indicated
that the development and implementation of a protocol
for stress ulcer prophylaxis, for which there are currently
no criteria, might improve therapeutic outcomes.
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